Tenet Healthcare Q3 revenue beats on same-store sales growth

By Reuters News


Overview

  • US hospital operator's Q3 net operating revenue rose 6.5%, beating analyst expectations

  • Adjusted EPS for Q3 jumped 79.5%, beating analyst expectations

  • Company raised FY 2026 adjusted EBITDA outlook


Outlook

  • Tenet raises FY 2026 adj EBITDA outlook to $5.05 bln-$5.20 bln from prior view

  • Company lifts FY 2026 adj free cash flow outlook to $2.825 bln-$3.125 bln


Result Drivers

  • SAME-STORE REVENUE GROWTH - Co said sustained strength in same-store revenue growth drove Q3 results, per CEO Saum Sutaria

  • EXPENSE MANAGEMENT - Co attributed margin improvement to disciplined expense management and operating initiatives

  • RCM AGREEMENTS TRANSITION - Timing-related adjustments and transition activities under RCM Agreements contributed $147 mln favorable net impact to Q3 Adjusted EBITDA


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Net Operating Revenue

Beat

$5.63 bln

$5.52 bln (18 Analysts)

Q3 Adjusted EPS

Beat

$6.64

$4.62 (20 Analysts)

Q3 EPS

$12.41


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 20 "strong buy" or "buy", 4 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the healthcare facilities & services peer group is "buy"

  • Wall Street's median 12-month price target for Tenet Healthcare Corp is $285.00, about 6.1% above its October 28 closing price of $268.50

  • The stock recently traded at 13 times the next 12-month earnings vs. a P/E of 11 three months ago


Reuters Recommended Reads

  • Oct 27 - Universal Health warns of possible impact to annual results from Medicaid changes; Q3 revenue slightly beats

  • Oct 28 - Community Health Systems Q3 revenue misses estimates

  • Oct 27 - HCA signals flat 2027 earnings as Medicaid payments drop; shares slide


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.